In endemic communities with prevalence of Schistosoma spp. infection ≥ 10% that demonstrate lack of an appropriate response to annual preventive chemotherapy, despite adequate treatment coverage (≥ 75%), WHO suggests consideration of biannual (twice yearly) instead of annual preventive chemotherapy.